Tuesday, two women pleaded guilty in a Polish court to handing a health fund official a trip worth more than $1,000 in exchange for backing the sale of a certain drug. And one of those women was a Novartis employee, the company said Thursday.
Now, it's Sanofi digging into potential bribery in the Middle East. The French drugmaker told U.S. officials that it's eyeing allegations from an anonymous whistleblower about improper payments from 2007 to 2012.
In a diversification bid, Charlotte, NC-based Carlisle Companies purchased Singapore's LHi Technology, a device industry supplier focused on cable manufacturing, for $195 million.
Indian CRO GVK Biosciences is working to get back in the good graces of European regulators after inspectors found evidence that its employees doctored clinical trial results.
Price caps on "essential drugs" in India have been a sore point with domestic as well as Big Pharma players. The industry was further enraged when an Indian agency in May assumed the authority to add other products to the 350 already restricted. But the government of Prime Minister Narendra Modi is reining in the National Pharmaceutical Pricing Authority (NPPA), suggesting he may have a less populous approach to the industry than his predecessor.
As promised, newcomer COO Christophe Weber is shaking things up at Takeda Pharmaceutical, with the Japanese company this week rolling out a revamped organizational structure that it hopes will make it the "best-in-class company in every aspect" of its business. And that includes vaccines.
Cheap Sovaldi is on the way, and it could very well be coming to an emerging market near you. Gilead has ironed out a licensing deal for the hep C wonder with 7 companies--including Mylan and Ranbaxy--and they'll bring low-cost copies to 91 developing countries.
Abbott Laboratories will invest $60 million in an intraocular lens manufacturing plant in Malaysia. The plant is expected to employ about 500 people and to be operational next year, producing 1 million sets of IOLs a year.
Blackberry is launching an ambitious project to integrate thousands of medical devices in India in order to detect illnesses earlier.
Turns out it's not just India and Egypt that will be getting price breaks on Gilead's hep C star, Sovaldi. The drugmaker is close to reaching an agreement with generics makers to bring low-cost versions of the $84,000 wonder drug to about 80 developing countries, according to EVP Gregg Alton.